Clinical Trial Update: Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1 [Phase 1, Phase 2]

View source ↗

Summary

This Phase 1/2 clinical trial evaluates FCN-159 in adults and children with Neurofibromatosis type 1 and plexiform neurofibroma to assess safety, tolerability, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neurofibromatosis Type
• Plexiform Neurofibroma

Drugs mentioned

• FCN-159

Snippet

Sponsor: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Conditions: Neurofibromatosis 1, Plexiform Neurofibroma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING